HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.6%

Neg 0% Neu 90.6% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.